 | |
 | |
| Clinical data | |
|---|---|
| Other names | N-(2-Diethylcarbamoylethyl)-N-methyl-4,α-methylenetryptamine;N-(3-Diethylamino-3-oxopropyl)-N-methyl-4,α-methylenetryptamine; 9-Nor-LSD; 9-Desmethine-LSD; 8,10-Seco-LSD |
| Drug class | Serotonergic psychedelic;Hallucinogen;Simplified/partial LSD analogue |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| PubChemCID | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H27N3O |
| Molar mass | 313.445 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
NDTDI, also known as9-desmethine-LSD,9-nor-LSD, or8,10-seco-LSD, is apsychedelic drug related tolysergic acid diethylamide (LSD).[1][2][3][4] It is atricycliccyclized tryptamine andpartial lysergamide and is astructurallysimplifiedanalogue of LSD.[2] The drug is specifically the analogue of LSD in which thecarbonatom at position 9 of theergolinering system has been removed.[2] It has been reported to produce psychedelic effects similarly to LSD, but with much lowerpotency.[1] Thepharmacology of NDTDI has not been studied. NDTDI was encountered as a noveldesigner drug by 2016.[1][3][4]
Analogues of NDTDI includeRU-27849,RU-28306,RU-28251,Bay R 1531 (LY-197206),LY-293284, andLY-178210. Otherpartial/simplified lysergamides includeDEIMDHPCA (4-nor-LSD),DEMPDHPCA (dides-B,C-LSD), and10,11-seco-LSD, among others. Deletion of the carbon at positions 9 and 10 of the ergoline ring system result in a fully non-rigid tryptamine derivative,N-DEAOP-NMT (9,10-dinor-LSD).[5][6]
NDTDI has been sold as adesigner drug since 2016 and was first identified by aforensiclaboratory inSlovenia in 2017.[3] NDTDI was made illegal inLatvia in March 2017.[4][7]
NDTDI is not an explicitly nor implicitlycontrolled substance inCanada as of 2025.[8]
NDTDI is not an explicitlycontrolled substance in theUnited States.[9] However, it could be considered a controlled substance under theFederal Analogue Act if intended for human consumption.
Sklar, et al. (53) found the diethylacrylamide adduct 20 to be approximately 1/10 as active as LSD in mice, although Norris and Blicke (54) reported 21 to have little oxytocic activity. [...] 20 = R = C2H5. 21 = R = CH3 [...]
Six esters and amides of derivatives of β-alanine which are related to lysergic acid have been prepared and tested for oxytocic activity. None of these products possess a significant oxytocic activity. [...] The purpose of this investigation was to synthesize amides and also esters of compounds (II–V) which represent fragments of the lysergic acid molecule in the hope that some of these products might possess oxytocic activity. Various modified fragments of the lysergic acid molecule have been synthesized previously; it was claimed that some of the compounds are active oxytocics (1—7). [...] Pharmacologic data indicated that none of the esters or amides of compounds II—V which were prepared possess a significant oxytocic action when compared to the clinically used oxytocics. However, the diethylamide of N-methyl-N-[β′-(3-indolyl)-ethyl]-β-alanine (IIIc) appeared to have an oxytocic activity approximately ten times stronger than that of the diethylamide of N-methyl-N-(β′-phenethyl)-β-alanine (IIc).
